

# **COST Action CA18218 European Burden of Disease Network**








# 357 members




# 38+20 countries


















#### https://www.burden-eu.net/eph2021





#### https://www.burden-eu.net/news/spotlight

**The burden-eu COST Action wants to put its members in the spotlight!** Spotlights are short (500-1000 words) blogposts where network members present their work in a personal and vulgarizing way. The spotlights also describe how the presented work benefited from the COST Action.

Do you have a recent publication or new project related to burden of disease? Please let us know via info@burden-eu.net, and we will be happy to put you in the spotlight!


Santé Publique France - National burden of disease study for France



Sarah Cuschieri - Experiences of the network from Malta



Alexander Rommel - BoCO-19: Towards a harmonization of population health metrics for the surveillance of dynamic outbreaks



Aline Anton - Estimating headache prevalence and severity in Germany




Lea Sletting Jakobsen - Impact of dairy consumption in the Danish population



Zubair Kabir - Development of a Global Burden of Disease-Frailty Index





#### https://www.burden-eu.net/outputs/covid-19

#### COVID-19

COVID-19 has affected many countries in Europe in beyond. There is currently a growing interest to quantify the disease burden of COVID-19, measure its population health impact and compare it to other diseases. On this page, we compile burden of disease resources specifically fo

#### **Burden of COVID-19 Task Force**

The Burden of COVID-19 Task Force brings together members who are conducting or interested in launching national studies to estimate to of COVID-19. The TF meets approximately every six weeks to discuss technical aspects of COVID-19 burden calculation.

More information about the Task Force is available here.

#### Burden of COVID-19 calculation protocol

The burden-eu Core Group has prepared a protocol to provide guidance for anyone planning to assess the burden of disease of COVIDALYS. It focuses on the direct health impact of the disease, and describes the data requirements, the methods, and considerations for the last also aims to foster harmonization of methodologies for estimating the burden of disease of COVID-19 across countries.

You can download the protocol here.

#### **Burden of COVID-19 webinars**

On Friday 20 November 2020, our COST Action has organized a webinar on quantifying COVID-19 disease burden. You can replay presentations here.

#### **Burden of COVID-19 publications**

DALY calculation methods for COVID-19

Wyper GM, Assunção RM, Colzani E, Grant I, Haagsma JA, Lagerweij G, Von der Lippe E, McDonald SA, Pires SM, Porst M, Speybroeck N, Devleesschauwer B. **Burden of disease methods: a guide to calculate COVID-19 disability-adjusted life years**. *Int J Public Health*. 2021;66:619011. doi: 10.3389/ijph.2021.619011



RESEARCH Open Access

### Estimating the direct Covid-19 disabilityadjusted life years impact on the Malta population for the first full year



Sarah Cuschieri<sup>1\*</sup>, Neville Calleja<sup>2,3</sup>, Brecht Devleesschauwer<sup>4,5</sup> and Grant M. A. Wyper<sup>6</sup>

Measuring the direct population impact of COVID-19 in Scotland, 2020: estimating disability-adjusted life years (DALYs) during the first full calendar year

Grant MA Wyper<sup>1,\*</sup>, Eilidh Fletcher<sup>2</sup>, Ian Grant<sup>2</sup>, Gerry McCartney<sup>1</sup>, Colin Fischbacher<sup>3</sup>, Oliver Harding<sup>4</sup>, Hannah Jones<sup>1</sup>, Maria Teresa de Haro Moro<sup>2</sup>, Niko Speybroeck<sup>5</sup>, Brecht Devleesschauwer<sup>6,7</sup>, Diane L Stockton<sup>1</sup>

The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years


Scott A. McDonald<sup>1</sup>, Giske R. Lagerweij<sup>1</sup>, Pieter de Boer<sup>1</sup>, Hester E. de Melker<sup>1</sup>, Roan Pijnacker<sup>1</sup>, Lapo Mughini Gras<sup>1</sup>, Mirjam E. Kretzschmar<sup>1,2</sup>, Gerco den Hartog<sup>1</sup>, Arianne B. van Gageldonk-Lafeber<sup>1</sup>, RIVM COVID-19 surveillance and epidemiology team<sup>1</sup>, Susan van den Hof<sup>1</sup>, Jacco Wallinga<sup>1,3</sup>



### [Webinar] Measuring the burden of rare diseases

Tuesday 14 September 2021, 9h-10h30 CET

Read more:



[Webinar] Forecasting the Global Burden of Disease Study

Tuesday 29 June 2021, 16h-17h CET

Read more:



[Webinar] Burden of disease assessment for COVID-19: initial insights and future perspectives

Friday 21 May 2021, 14h-15h CET

Read more:

## www.burden-eu.net/webinars



### [Webinar] Activities and achievements of the Italian GBD Initiative

Thursday 29 April 2021, 13h-14h CET

Read more:



[Webinar] Elicitation and practical use of disability weights for quantifying years lived with disability

Thursday 14 January 2021, 13h-14h CET

Read more:




### [Webinar] Quantifying COVID-19 disease burden

Friday 20 November 2020, 11h-12h CET

Read more:







Measuring disability-adjusted life years (DALYs) due to low back pain in Malta

Cuschieri S, Wyper GMA, Calleja N, Gorasso V, Devleesschauwer B

Arch Public Health. 2020;78:68





Haneef R, Schmidt J, Gallay A, Devleesschauwer B, Grant I, Rommel A, Wyper GMA, van Oyen H, Hilderink H, Ziese T. Newton J

Arch Public Health. 2021;79:126



Burden of non-communicable diseases in Cyprus, 1990-2017: findings from the Global Burden of Disease 2017 study

Charalampous P, Pallari E, Tyrovolas S, Middleton N, Economou M, Devleesschauwer B, Haagsma JA

Arch Public Health. 2021;79:138



Population vulnerability to COVID-19 in Europe: a burden of disease analysis

Wyper GM, Assunção RM, Cuschieri S, Devleeschauwer B, Fletcher E, Haagsma JA, Hilderink H, Idavain J, Lesnik T, Von der Lippe E, Majdan M, Santric-Milicevic M, Pallari E, Peñalvo JL, Pires SM, Plass D, Santos JV, Stockton DL, Thomsen ST, Grant I

Arch Public Health. 2020;78:47





Burden of foodborne diseases: think global, act local

Pires SM, Desta BN, Mughini-Gras L, Mmbaga BT, Fayemi OE, Salvador EM, Gobena T, Majowicz SE, Hald TM, Hoejskov PS, Minato Y, Devleesschauwer B Curr Opin Food Sci. 2021;39:152-159

@ 9 m G



Estimating the direct Covid-19 disability-adjusted life years impact on the Malta population for the first full

Cuschieri S, Calleja N, Devleesschauwer B, Wyper GMA BMC Public Health. 2021;;21:1827





Health expectancies in the European Union: same concept, different methods, different results

Santos JV, Viana J, Devleesschauwer B, Haagsma J, Costa-Santos C, Ricciardi W, Freitas A

J Epidemiol Community Health. 2021;75:764-771






in the European Union (EU-28) countries in 2007 and

Santos JV, Gorasso V, Souza J, Wyper GMA, Grant I, Pinheiro V, Viana J, Ricciardi W, Haagsma JA, Devleesschauwer B, Plass D, Freitas A

Eur J Public Health. 2021; in press





Devleesschauwer B, McDonald S, Speybroeck N, Wyper **GMA** 

Int J Public Health. 2020;65:719-720





Reflections on key methodological decisions in national burden of disease assessments

von der Lippe E, Devleesschauwer B, Gourley M, Haagsma J, Hilderink H, Porst M, Wengler A, Wyper G, Grant I

Arch Public Health. 2020;78:137



The increasing significance of disease severity in a burden of disease framework

Wyper G, Assunçao R, Fletcher E, Gourley M, Grant I, Haagsma J, Hilderink H, Idavain J, Lesnik T, von der Lippe E, Majdan M, McCartney G, Pallari E, Pires S, Plass D, Porst M, Santos J, Santric-Milicevic M, de Haro Moro MT, Stockton D, Devleesschauwer B

Scand J Public Health. 2021; in press



Burden of disease methods: a guide to calculate COVID-19 disability-adjusted life years

Wyper GMA, Assunçao RMA, Colzani E, Grant I, Haagsma JA, Lagerweij G, Von der Lippe E, McDonald SA, Pires SM, Porst M, Speybroeck N, Devleesschauwer B

Int J Public Health. 2021;66:619011



Conducting national burden of disease studies in small countries in Europe- a feasible challenge?

Cuschieri S, Pallari E, Terzic N, Alkerwi A, Sigurvinsdottir R, Sigfusdottir ID, Devleesschauwer B

Arch Public Health. 2021;79:73





European burden of disease network: strengthening the collaboration

**Devleesschauwer B** 

Eur J Public Health. 2020;30:2-3







## Our experience

- Unique opportunity for networking and capacity building
  - Network still growing !
- Platform for preparing new project proposals
- Administrative burden
- How to keep large network involved?
- COVID has a big impact, but we adapted via new online tools
- Need careful reflection on options for sustainability



# Tips and tricks

On getting your proposal accepted (and ensuring a smooth implementation of the Action)





## Tips and tricks

- 1. Be part of a COST Action
- 2. Have a real need for a network
- 3. Remain anonymous
- 4. Implement COST tools & policies
- 5. Write the proposal for the reviewers
- 6. Define realistic objectives and deliverables
- 7. Know your WG leaders

### Be part of a COST Action

Grant Holder

COST Action Chair and Co-Chair

Transversal Coordinators STSM, SciCom


WG Leaders and Co-Leaders

**Core Group** 

**Management Committee** Members

Working Group Members

### Have a real need for network



## Remain anonymous


### Implement COST tools

VIRTUAL MOBILITY GRANTS

SHORT TERM SCIENTIFIC MISSIONS

ITC CONFERENCE GRANTS


TRAINING SCHOOLS



## Implement COST policies



### Write for the reviewers



#### Description

What are the most relevant diseases in a country? Which risk factors are the strongest contributors to disease and death? How is the impact of different diseases evolving over time, and how does it compare between countries and within subnational units? As the need for prioritising the use of available resources constantly increases, a timely, sound and comprehensive answer to these fundamental questions is more than ever needed to inform public health decision making. Driven by the impact of the Global Burden of Disease study, several researchers and national and international health institutes have adopted the burden of disease approach to address these questions.

The complexity of the burden of disease approach however resulted in major disparities in research capacity across Europe. The burden-eu COST Action will address current challenges by 1) stimulating interaction between existing efforts, 2) supporting technical capacity building at country level,

#### **Action Details**

- MoU 035/19
- CSO Approval date 04/06/2
- Start date 28/10/20
- **End date 27/10/2023**
- https://www.burden-eu.net/

### Define realistic objectives

#### Research Coordination

- To bring together experts and expertise across different domains, transforming the currently scattered burden of disease landscape into one transnational team.
- To compare and harmonize methods and approaches for burden of disease assessment.
- To identify critical knowledge and data gaps, and set up studies for which international coordination is needed
- To serve as an advocacy group for the burden of disease approach in Europe.


#### Capacity Building

- To build and increase capacity in burden of disease assessment across Europe. The Action will have an
  explicit focus on the involvement of specific target groups, including Early Career Investigators, the underrepresented gender, and teams and countries with less capacity in the field of burden of disease.
- To serve as a technical platform where knowledge and expertise can be shared among established and emerging researchers.
- To promote an interdisciplinary approach that integrates knowledge translation in the classical burden of

### Define realistic deliverables

#	Deliverable	Deadline
1	Development of the Action's website	M6
2	Development of communication and dissemination strategy	M6
3	Development of checklist for burden of disease studies	M15
4	Development of burden of disease training material	M21
5	Development of national burden of disease roadmap	M36
6	Identification and involvement of BOD researchers	M48
7	Compilation of burden of disease studies	M48
8	Compilation of knowledge translation good practices	M48
9	Development of joint BOD research agenda	M48

## Know your WG leaders





# **COST Action CA18218 European Burden of Disease Network**





www.burden-eu.net

